Abrocitinib Therapeutic Cheat Sheet
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory …
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
ABSTRACT
Post-hyaluronic acid filler nodules are uncommon, unpredictable complications that present a challenge to clinical therapy. JDD authors Miyahra Haniko P. Lopez MD MBA, Sophie H. Guenin MSc, Jennifer Laborada BS, and Mark G. Lebwohl MD report a case of a female in her fifties who developed edema and nodules 6 weeks after hyaluronic acid (HA) filler injection. After minimal improvement wit … 
The Journal of Drugs in Dermatology welcomes 2024 with a strong line up of original articles, case reports, brief communications, and letters to the editor. Straight from the Editor's desk, we share this month's issue highlights!
ORIGINAL ARTICLES
Current Landscape of Hyaluronic Acid Filler Use in the United States shares the results of a comprehensive search of all the FDA approved dermal fill … 
Dr. Friedman, jack of many trades, Professor and Interim Chair of Dermatology at George Washington University provided an excellent overview of ways to achieve victory over atopic dermatitis (AD). This expert discussion took place during the ODAC Inflammatory Diseases Symposium on December 3, 2020.
How could we possibly cover atopic dermatitis in 20 minutes? Well, Dr. Friedman skillfully led us …